WRAL Tech Wire

Drutz to chair Gentris board

The company said Dr. David J. Drutz has been elected chairman, and entrepreneur and accountant Tim Gupton has joined the board.

Merck to close former Inspire HQ in Raleigh, cut 51 workers

The drug giant recently purchased Raleigh-based Inspire Pharmaceuticals. In a notice filed with the state, the expected closure of Inspire's offices is made official.

Merck wraps up $430M Inspire deal, will close Raleigh HQ

Some company executives will be leaving the eye drug firm as it is absorbed by the pharmaceutical giant.

Inspire reports $17.6M quarterly loss after restructuring

The Raleigh-based pharmaceutical firm, which is in the process of being acquired by drug giant Merck, says losses increased nearly $3 million from a year ago.

Merck's $430M buy triggers Inspire stock frenzy

Merck will pay $5 a share for Inspire. Both boards and a major Inspire investor have already approved the deal. Inspire's shares collapsed in January after a failed drug trial.

Tech briefs: Inspire Pharmaceuticals, Dex One, Nexxus Lighting, NC toll road devices

Inspire offers bonuses; Dex One seeks feedback on executive pay; Lowes to sell Nexxus LED lighting; NC toll roll RFID devices clear tests.

Inspire drops lung drug, cuts 65 positions

Inspire Pharmaceuticals said Thursday that it is laying off 65 people, or 27 percent of its work force related to the drug's development.

Analyst cuts Inspire after failed clinical trial

Shares in the Raleigh-based pharmaceutical firm plunged Monday on news of a failure for its drug targeting cystic fibrosis.

Meltdown: Inspire Pharmaceutical shares down 59%

The company, which just moved to Raleigh, says its candidate for treatment of cystic fibrosis fails to meet efficacy goals in Phase III clinical trial.

$1.25M payday for Inspire - Dry eye drug launches in Japan

The Durham-based pharmaceutical firm's partner in Japan receives approval to launch Diquas. That news triggers a milestone payment plus future royalties.

Inspire cuts losses, beats Street expectations

The Durham-based pharmaceutical firm loses far less than forecast - 9 cents per share rather than 14 cents as expected.

Inspire Pharmaceuticals names chief technical officer

Inspire, Allergan revise licensing agreement for eye drugs

The Durham-based firm regains control of failed drug candidate Prolacria. Inspire also will receive smaller royalties from Allegran for sales of eye drug Restasis.

Inspire Pharmaceuticals names chief medical officer

Inspire Pharmaceuticals’ head of research and development is stepping down